- Country: USA
- Summary: Clinical Studies of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects
- UST Ref No: 113293017
- Deadline: 30 Jan 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 75N93025R00014
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
The National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Laboratory of Infectious Diseases (LID) have been performing clinical studies in adult and/or pediatric volunteer populations since the 1950's, with the goal of developing safe and effective vaccines against influenza viruses, human parainfluenza viruses (HPIV), respiratory syncytial viruses (RSV), human metapneumovirus (HMPV), viral agents of gastroenteritis, and flaviviruses. These studies have identified promising candidate vaccines against RSV and other viruses, leading to Cooperative Research And Development Agreements (CRADAs) with commercial collaborators. Safe and immunogenic live-attenuated vaccines against all four dengue virus serotypes were identified and combined into a single-dose tetravalent vaccine, leading to licensing agreements in Brazil, India, Bangladesh, Vietnam, Taiwan, and the US. A Phase 3 study of the lead tetravalent dengue vaccine formulation was recently completed in Brazil, a Phase 3 study is currently underway in India, and other Phase 2 studies are being conducted in Bangladesh, India, and the US.
LID and the Laboratory of Viral Diseases (LVD) of NIAID require clinical trials to investigate the safety, immunogenicity, and protective efficacy of vaccines against pneumoviruses, paramyxoviruses (primarily HPIVs), influenza viruses, flaviviruses, alphaviruses, and bunyaviruses, including newly emerging viruses such as Zika virus, noroviruses, rotavirus, and virally-vectored vaccines. Vaccine studies will include adult and pediatric subjects. Clinical trials in adults may also be required for pathogenesis research and to develop viral human challenge models for the testing of antivirals and vaccines. - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINClinical Studies of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Clinical Studies of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects. This tender is published on USARFP under UST Ref No: 113293017 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-30.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
